Top

Published in:

01-09-2019 | Melanoma | Original Article

Melanoma-conditioned medium promotes cytotoxic immune responses by murine bone marrow-derived monocytes despite their expression of ‘M2’ markers

Authors: Liam Friel Tremble, Anne C. Moore, Patrick F. Forde

Published in: Cancer Immunology, Immunotherapy | Issue 9/2019

Abstract

Macrophages have been shown to infiltrate a wide range of malignancies and are often considered to promote tumour survival, growth and spread. However, the source and behaviour of discrete tumour-associated macrophage populations are still poorly understood. Here we show a novel method for the rational development of bone marrow-derived monocytes appropriate for the study of processes which involve the contribution of circulating inflammatory monocytes. We have shown that in response to tumour-conditioned medium, these cells upregulate CD206 and CD115, markers traditionally associated with M2-type macrophages. Treated cells show reduced capacity for cytokine secretion but significantly impact CD4⁺ and CD8⁺ T-cell proliferation and polarization. Coculture with conditioned bone marrow-derived monocytes significantly reduced CD4⁺ T-cell proliferation but increased CD8⁺ T-cell proliferation and granzyme B expression with significant induction of IFNγ secretion by both CD4⁺ and CD8⁺ T cells, indicating that these cells may have a role in promoting anti-cancer immunity.

Available only for authorised users

Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41(1):14–20. https://doi.org/10.1016/j.immuni.2014.06.008 CrossRefPubMedPubMedCentral

Mills CD (2012) M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol 32(6):463–488CrossRefPubMed

Tremble LF, Forde PF (2017) Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges. Cancer Immunol Immunother 66(12):1509–1527. https://doi.org/10.1007/s00262-017-2065-0 CrossRefPubMed

Lee CM, Hu J (2013) Cell density during differentiation can alter the phenotype of bone marrow-derived macrophages. Cell Biosci 3:30. https://doi.org/10.1186/2045-3701-3-30 CrossRefPubMedPubMedCentral

Rostam HM, Singh S, Salazar F, Magennis P, Hook A, Singh T, Vrana NE, Alexander MR, Ghaemmaghami AM (2016) The impact of surface chemistry modification on macrophage polarisation. Immunobiology 221(11):1237–1246. https://doi.org/10.1016/j.imbio.2016.06.010 CrossRefPubMed

Shima M, Teitelbaum SL, Holers VM, Ruzicka C, Osmack P, Ross FP (1995) Macrophage-colony-stimulating factor regulates expression of the integrins alpha 4 beta 1 and alpha 5 beta 1 by murine bone marrow macrophages. Proc Natl Acad Sci USA 92(11):5179–5183CrossRefPubMedPubMedCentral

Geissmann F, Jung S, Littman DR (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19(1):71–82CrossRefPubMed

Yang J, Zhang L, Yu C, Yang X-F, Wang H (2014) Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2(1):1. https://doi.org/10.1186/2050-7771-2-1 CrossRefPubMedPubMedCentral

Zheng J, Yang M, Shao J, Miao Y, Han J, Du J (2013) Chemokine receptor CX3CR9 contributes to macrophage survival in tumor metastasis. Mol Cancer 12(1):141. https://doi.org/10.1186/1476-4598-12-141 CrossRefPubMedPubMedCentral

10.

Richards DM, Hettinger J, Feuerer M (2012) Monocytes and macrophages in cancer: development and functions. Cancer Microenviron 6(2):179–191. https://doi.org/10.1007/s12307-012-0123-x CrossRefPubMedPubMedCentral

11.

Haanen JBAG (2013) Immunotherapy of melanoma. EJC Suppl 11(2):97–105. https://doi.org/10.1016/j.ejcsup.2013.07.013 CrossRefPubMedPubMedCentral

12.

Flecknell P (2002) Replacement, reduction and refinement. Altex 19(2):73–78PubMed

13.

Flesch IE, Kaufmann SH (1999) Effect of fetal calf serum on cytokine release by bone marrow-derived macrophages during infection with intracellular bacteria. Immunobiology 200(1):120–127. https://doi.org/10.1016/s0171-2985(99)80037-0 CrossRefPubMed

14.

Bertani FR, Mozetic P, Fioramonti M, Iuliani M, Ribelli G, Pantano F, Santini D, Tonini G, Trombetta M, Businaro L, Selci S, Rainer A (2017) Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis. Sci Rep 7(1):8965. https://doi.org/10.1038/s41598-017-08121-8 CrossRefPubMedPubMedCentral

15.

Saha B, Bruneau JC, Kodys K, Szabo G (2015) Alcohol-induced miR-27a regulates differentiation and M2 macrophage polarization of normal human monocytes. J Immunol 194(7):3079–3087. https://doi.org/10.4049/jimmunol.1402190 CrossRefPubMed

16.

Soncin I, Sheng J, Chen Q, Foo S, Duan K, Lum J, Poidinger M (2018) The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma. Nat Commun 9(1):582. https://doi.org/10.1038/s41467-018-02834-8 CrossRefPubMedPubMedCentral

17.

Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A (2012) Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR17-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 189(12):5602–5611. https://doi.org/10.4049/jimmunol.1201018 CrossRefPubMed

18.

Grossman JG, Nywening TM, Belt BA, Panni RZ, Krasnick BA, DeNardo DG, Hawkins WG, Goedegebuure SP, Linehan DC, Fields RC (2018) Recruitment of CCR18(+) tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. Oncoimmunology 7(9):e1470729. https://doi.org/10.1080/2162402x.2018.1470729 CrossRefPubMedPubMedCentral

19.

Sun LX, Li WD, Lin ZB, Duan XS, Xing EH, Jiang MM, Yang N, Qi HH, Sun Y, Li M, Niu YD, Lu J (2015) Cytokine production suppression by culture supernatant of B16F10 cells and amelioration by Ganoderma lucidum polysaccharides in activated lymphocytes. Cell Tissue Res 360(2):379–389. https://doi.org/10.1007/s00441-014-2083-6 CrossRefPubMed

20.

Bardi GT, Smith MA, Hood JL (2018) Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine 105:63–72. https://doi.org/10.1016/j.cyto.2018.02.002 CrossRefPubMedPubMedCentral

21.

Zhang F, Wang H, Wang X, Jiang G, Liu H, Zhang G, Wang H, Fang R, Bu X, Cai S, Du J (2016) TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget 7(32):52294–52306. https://doi.org/10.18632/oncotarget.10561 CrossRefPubMedPubMedCentral

22.

Wan YY, Flavell RA (2008) TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol 28(6):647–659. https://doi.org/10.1007/s10875-008-9251-y CrossRefPubMedPubMedCentral

23.

Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180(9):5771–5777. https://doi.org/10.4049/jimmunol.180.9.5771 CrossRefPubMed

24.

Maybruck BT, Pfannenstiel LW, Diaz-Montero M, Gastman BR (2017) Tumor-derived exosomes induce CD8(+) T cell suppressors. J Immunother Cancer 5(1):65. https://doi.org/10.1186/s40425-017-0269-7 CrossRefPubMedPubMedCentral

25.

Klarquist J, Tobin K, Farhangi Oskuei P, Henning SW, Fernandez MF, Dellacecca ER, Navarro FC, Eby JM, Chatterjee S, Mehrotra S, Clark JI, Le Poole IC (2016) Ccl22 diverts T regulatory cells and controls the growth of melanoma. Cancer Res 76(21):6230–6240. https://doi.org/10.1158/0008-5472.CAN-16-0618 CrossRefPubMedPubMedCentral

26.

Chen M-L, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 102(2):419–424. https://doi.org/10.1073/pnas.0408197102 CrossRefPubMed

27.

Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V (2015) Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer 136(10):2352–2360. https://doi.org/10.1002/ijc.29297 CrossRefPubMed

28.

Gerber AL, Munst A, Schlapbach C, Shafighi M, Kiermeir D, Husler R, Hunger RE (2014) High expression of FOXP3 in primary melanoma is associated with tumour progression. Br J Dermatol 170(1):103–109. https://doi.org/10.1111/bjd.12641 CrossRefPubMed

29.

Baumgartner JM, Gonzalez R, Lewis KD, Robinson WA, Richter DA, Palmer BE, Wilson CC, McCarter MD (2009) Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res 154(1):13–20. https://doi.org/10.1016/j.jss.2008.04.043 CrossRefPubMed

30.

Tucci M, Mannavola F, Passarelli A, Stucci LS, Cives M, Silvestris F (2018) Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget 9(29):20826–20837. https://doi.org/10.18632/oncotarget.24846 CrossRefPubMedPubMedCentral

31.

Bland CL, Byrne-Hoffman CN, Fernandez A, Rellick SL, Deng W, Klinke DJ 2nd (2018) Exosomes derived from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial respiration. FEBS J 285(6):1033–1050. https://doi.org/10.1111/febs.14396 CrossRefPubMedPubMedCentral

32.

Zhang L, Tao L, Shi T, Zhang F, Sheng X, Cao Y, Zheng S, Wang A, Qian W, Jiang L, Lu Y (2015) Paeonol inhibits B16F10 melanoma metastasis in vitro and in vivo via disrupting proinflammatory cytokines-mediated NF-κB and STAT3 pathways. IUBMB Life 67(10):778–788. https://doi.org/10.1002/iub.1435 CrossRefPubMed

33.

Kruger-Krasagakes S, Krasagakis K, Garbe C, Diamantstein T (1995) Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res 139:155–168CrossRefPubMed

Title: Melanoma-conditioned medium promotes cytotoxic immune responses by murine bone marrow-derived monocytes despite their expression of ‘M2’ markers
Authors: Liam Friel Tremble
Anne C. Moore
Patrick F. Forde
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Melanoma
Melanoma
Published in: Cancer Immunology, Immunotherapy / Issue 9/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02381-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2019

Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature

Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer

Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells

TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma

Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer